Cargando…

Bifidobacterium adolescentis Alleviates Liver Steatosis and Steatohepatitis by Increasing Fibroblast Growth Factor 21 Sensitivity

The gut microbiota is a newly identified contributor to the development of non-alcoholic fatty liver disease (NAFLD). Previous studies of Bifidobacterium adolescentis (B. adolescentis), a species of Bifidobacterium that is common in the human intestinal tract, have demonstrated that it can alleviate...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Xiaoxue, Liu, Dan, Gao, Qiongmei, Ni, Jiacheng, Qian, Lingling, Ni, Yueqiong, Fang, Qichen, Jia, Weiping, Li, Huating
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756294/
https://www.ncbi.nlm.nih.gov/pubmed/35035378
http://dx.doi.org/10.3389/fendo.2021.773340
_version_ 1784632540367159296
author Long, Xiaoxue
Liu, Dan
Gao, Qiongmei
Ni, Jiacheng
Qian, Lingling
Ni, Yueqiong
Fang, Qichen
Jia, Weiping
Li, Huating
author_facet Long, Xiaoxue
Liu, Dan
Gao, Qiongmei
Ni, Jiacheng
Qian, Lingling
Ni, Yueqiong
Fang, Qichen
Jia, Weiping
Li, Huating
author_sort Long, Xiaoxue
collection PubMed
description The gut microbiota is a newly identified contributor to the development of non-alcoholic fatty liver disease (NAFLD). Previous studies of Bifidobacterium adolescentis (B. adolescentis), a species of Bifidobacterium that is common in the human intestinal tract, have demonstrated that it can alleviate liver steatosis and steatohepatitis. Fibroblast growth factor 21 (FGF21) has long been considered as a biomarker of NAFLD, and recent studies have shown the protective effect of FGF21 analogs on NAFLD. We wondered whether B. adolescentis treatment would alleviate NAFLD via the interaction with FGF21. To this end, male C57BL/6J mice on a choline-deficient high-fat diet (CDHFD) were treated with drinking water supplemented with B. adolescentis for 8 weeks, followed by the acute administration of recombinant mouse FGF21 protein (rmFGF21) to conduct the FGF21 response test. Consistent with previous studies, B. adolescentis supplementation reversed the CDHFD-induced liver steatosis and steatohepatitis. This was evaluated on the NAFLD activity score (NAS), reduced liver enzymes, and lipid accumulation. Further studies demonstrated that B. adolescentis supplementation preserved the gut barrier, reduced the gut microbiota-derived lipopolysaccharide (LPS), and inhibited the hepatic TLR4/NF-κB pathway. This was accompanied by the elevated expressions of the receptors of FGF21, fibroblast growth factor receptor 1 (FGFR1) and β-klotho (KLB), in the liver and the decreased expression of FGF21. The results of FGF21 response test showed that B. adolescentis supplementation alleviated the CDHFD-induced FGF21 resistance. In vivo experiments suggested that LPS could suppress the expression of FGF21 and KLB in a dose-dependent manner. Collectively, this study showed that B. adolescentis supplementation could alleviate NAFLD by increasing FGF21 sensitivity.
format Online
Article
Text
id pubmed-8756294
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87562942022-01-14 Bifidobacterium adolescentis Alleviates Liver Steatosis and Steatohepatitis by Increasing Fibroblast Growth Factor 21 Sensitivity Long, Xiaoxue Liu, Dan Gao, Qiongmei Ni, Jiacheng Qian, Lingling Ni, Yueqiong Fang, Qichen Jia, Weiping Li, Huating Front Endocrinol (Lausanne) Endocrinology The gut microbiota is a newly identified contributor to the development of non-alcoholic fatty liver disease (NAFLD). Previous studies of Bifidobacterium adolescentis (B. adolescentis), a species of Bifidobacterium that is common in the human intestinal tract, have demonstrated that it can alleviate liver steatosis and steatohepatitis. Fibroblast growth factor 21 (FGF21) has long been considered as a biomarker of NAFLD, and recent studies have shown the protective effect of FGF21 analogs on NAFLD. We wondered whether B. adolescentis treatment would alleviate NAFLD via the interaction with FGF21. To this end, male C57BL/6J mice on a choline-deficient high-fat diet (CDHFD) were treated with drinking water supplemented with B. adolescentis for 8 weeks, followed by the acute administration of recombinant mouse FGF21 protein (rmFGF21) to conduct the FGF21 response test. Consistent with previous studies, B. adolescentis supplementation reversed the CDHFD-induced liver steatosis and steatohepatitis. This was evaluated on the NAFLD activity score (NAS), reduced liver enzymes, and lipid accumulation. Further studies demonstrated that B. adolescentis supplementation preserved the gut barrier, reduced the gut microbiota-derived lipopolysaccharide (LPS), and inhibited the hepatic TLR4/NF-κB pathway. This was accompanied by the elevated expressions of the receptors of FGF21, fibroblast growth factor receptor 1 (FGFR1) and β-klotho (KLB), in the liver and the decreased expression of FGF21. The results of FGF21 response test showed that B. adolescentis supplementation alleviated the CDHFD-induced FGF21 resistance. In vivo experiments suggested that LPS could suppress the expression of FGF21 and KLB in a dose-dependent manner. Collectively, this study showed that B. adolescentis supplementation could alleviate NAFLD by increasing FGF21 sensitivity. Frontiers Media S.A. 2021-12-30 /pmc/articles/PMC8756294/ /pubmed/35035378 http://dx.doi.org/10.3389/fendo.2021.773340 Text en Copyright © 2021 Long, Liu, Gao, Ni, Qian, Ni, Fang, Jia and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Long, Xiaoxue
Liu, Dan
Gao, Qiongmei
Ni, Jiacheng
Qian, Lingling
Ni, Yueqiong
Fang, Qichen
Jia, Weiping
Li, Huating
Bifidobacterium adolescentis Alleviates Liver Steatosis and Steatohepatitis by Increasing Fibroblast Growth Factor 21 Sensitivity
title Bifidobacterium adolescentis Alleviates Liver Steatosis and Steatohepatitis by Increasing Fibroblast Growth Factor 21 Sensitivity
title_full Bifidobacterium adolescentis Alleviates Liver Steatosis and Steatohepatitis by Increasing Fibroblast Growth Factor 21 Sensitivity
title_fullStr Bifidobacterium adolescentis Alleviates Liver Steatosis and Steatohepatitis by Increasing Fibroblast Growth Factor 21 Sensitivity
title_full_unstemmed Bifidobacterium adolescentis Alleviates Liver Steatosis and Steatohepatitis by Increasing Fibroblast Growth Factor 21 Sensitivity
title_short Bifidobacterium adolescentis Alleviates Liver Steatosis and Steatohepatitis by Increasing Fibroblast Growth Factor 21 Sensitivity
title_sort bifidobacterium adolescentis alleviates liver steatosis and steatohepatitis by increasing fibroblast growth factor 21 sensitivity
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756294/
https://www.ncbi.nlm.nih.gov/pubmed/35035378
http://dx.doi.org/10.3389/fendo.2021.773340
work_keys_str_mv AT longxiaoxue bifidobacteriumadolescentisalleviatesliversteatosisandsteatohepatitisbyincreasingfibroblastgrowthfactor21sensitivity
AT liudan bifidobacteriumadolescentisalleviatesliversteatosisandsteatohepatitisbyincreasingfibroblastgrowthfactor21sensitivity
AT gaoqiongmei bifidobacteriumadolescentisalleviatesliversteatosisandsteatohepatitisbyincreasingfibroblastgrowthfactor21sensitivity
AT nijiacheng bifidobacteriumadolescentisalleviatesliversteatosisandsteatohepatitisbyincreasingfibroblastgrowthfactor21sensitivity
AT qianlingling bifidobacteriumadolescentisalleviatesliversteatosisandsteatohepatitisbyincreasingfibroblastgrowthfactor21sensitivity
AT niyueqiong bifidobacteriumadolescentisalleviatesliversteatosisandsteatohepatitisbyincreasingfibroblastgrowthfactor21sensitivity
AT fangqichen bifidobacteriumadolescentisalleviatesliversteatosisandsteatohepatitisbyincreasingfibroblastgrowthfactor21sensitivity
AT jiaweiping bifidobacteriumadolescentisalleviatesliversteatosisandsteatohepatitisbyincreasingfibroblastgrowthfactor21sensitivity
AT lihuating bifidobacteriumadolescentisalleviatesliversteatosisandsteatohepatitisbyincreasingfibroblastgrowthfactor21sensitivity